310 results about "Pneumonitis" patented technology

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The embodiment of the invention provides a traditional Chinese medicine preparation for improving lung qi and yin deficiency constitution and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: 1-3 parts of American ginseng, 2-15 parts of Chinese yam, 1.5-9 parts of codonopsis pilosula, 1-6 parts of dendrobium officinale, 1.5-9 parts of rhizoma polygonati, 0.5-2 parts of schisandra chinensis, 2-6 parts of lily, 1-3 parts of pericarpium citri reticulatae, 1-2 parts of liquorice, 1-5 parts of folium mori, 1-3 parts of donkey-hide gelatin, 1-3 parts of mint, 1-6 parts of angelica sinensis and 2-9 parts of coix seeds. Therefore, the traditional Chinese medicine composition has the functions of tonifying qi and yin, clearing heat and moistening lung, replenishing blood and promoting salivation, and relieving cough and reducing sputum, and can be widely applied to chronic cough, various pneumonia, pulmonary tuberculosis, chronic obstructive pulmonary disease, lung malignant tumor, asthma remission period of asthma, respiratory failure and other syndrome-differentiated lung qi and yin deficiency patients.

The invention belongs to the technical field of radiooncology, artificial intelligence and medical image fusion, and particularly relates to a model construction method and system for predicting the radiation pneumonitis risk of a patient receiving immune combined radiotherapy. According to the method, for a non-small cell lung cancer patient receiving immune checkpoint inhibitor (ICIs) combined radiotherapy, clinical information and radiotherapy dose parameters of the patient are collected, a positioning CT image and dynamic immune factor data are simulated, multi-source features including radiomics features, an immune change curve and dose volume indexes are extracted, and a multi-modal fusion prediction model is constructed. The system integrates automatic data input, feature extraction, model training and risk output modules, can output individual radiation pneumonitis risk scores, provides risk grading and dose intervention suggestions, and has high prediction accuracy and clinical interpretability. The method can be widely applied to individualized risk management and precise treatment of non-small cell lung cancer immune combined radiotherapy patients.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention discloses a lung function evaluation method for a patient in a pneumonia rehabilitation period, and relates to the technical field of rehabilitation management. Extracting a lung function feature set based on the image data; analyzing based on multi-dimensional parameter association, and establishing a dynamic mapping relationship between the lung function feature set and associated physiological parameters; identifying abnormal associated parameters through a dynamic mapping relation between the lung function feature set and the associated physiological parameters, and when the deviation between the image feature recovery degree and the corresponding physiological parameter recovery degree exceeds a preset threshold value, judging that functional abnormal parameters exist; and matching a potential complication database based on the abnormal parameter type, analyzing the relevance between the abnormal parameter and a preset disease feature model, and outputting secondary disease risk early warning. The method has the advantages that through cross-modal fusion of the lung image features and the dynamic physiological parameters, the early recognition precision of the pneumonia convalescence complication is remarkably improved.

The invention provides a pneumonia medical data analysis and processing method, system and device and a storage medium, and belongs to the field of medical image processing. Multi-scale features of the lung CT image are extracted layer by layer through convolution, global pooling operation down-sampling is carried out based on the multi-scale features, and saliency features of lung lobe and lesion areas are captured from local details to global semantics; performing convolution and multi-scale pooling on the saliency features to generate a feature map fusing global and local information; and recovering the feature map through layer-by-layer up-sampling to obtain a segmentation result of the lung lobe and the focus. Quantitative indicators are calculated based on regions and pixels of the segmentation results of the lung lobes and lesions. And performing model processing based on the quantitative index, the segmentation result of the lung lobe and the focus and clinical data of the lung lobe and the patient to obtain pneumonia focus characteristic data. And a doctor can conveniently make an objective and reasonable treatment scheme according to a result of lesion segmentation and feature data calculation based on the pneumonia lesion feature data.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention discloses a medical image segmentation method based on a Kolmogorov-Arnold network, and the method comprises the steps: firstly obtaining a medical image, then constructing an IKANet model, and carrying out the segmentation of the medical image after training, testing and verification. Wherein the IKANet model adopts an encoder-decoder structure and integrates three core components, namely a DKC module, a multi-scale attention module and an interpretability analysis module, and the DKC module realizes adaptive nonlinear transformation and feature decoupling through a Kolmogorov-Arnold network; the multi-scale attention module enhances space-channel feature fusion through multi-scale convolution and a channel attention mechanism; and the interpretability analysis module generates a multi-scale class activation mapping thermodynamic diagram and provides visual interpretation. The technical problems that an existing medical image segmentation method is limited in generalization ability and insufficient in interpretability are solved, and the method can be widely applied to data sets of colon polyp, pneumonia, pneumothorax and the like.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

Provided herein is a method for rapidly assessing a cattle patient for respiratory disease using targeted thoracic point-of-care ultrasound (TT-POCUS). This assessment begins with scanning a thoracic region of a lung of the cattle patient with an ultrasound probe to generate an ultrasound image. Subsequently, a count of A-lines and a count of B-lines are identified, along with the presence or absence of severe lung consolidation and / or abnormal pleural findings. The findings from the method can be used to distinguish interstitial pneumonia from non interstitial pneumonia, and predict future treatment success.

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The invention provides an application of a Ly6G antibody in treatment of pneumonia caused by novel coronavirus, and the Ly6G antibody can effectively reduce the lung inflammatory infiltration degree after novel coronavirus infection, reduce the expression level of cytokines, chemotactic factors or NETs related proteins, and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe pneumonia caused by multiple infection of novel coronavirus.

The invention provides a chest CT image automatic segmentation and interstitial pneumonia prediction method and system, and the method and system achieve the automatic segmentation of a CT image through deep learning, greatly improve the image analysis efficiency, reduce the error of manual intervention, and reduce the judgment deviation caused by subjective factors. Quantitative features are combined with a statistical model, small changes of lung images are effectively captured, and the accuracy of IP risk prediction is remarkably improved. According to test data, in a pneumonia patient sample, the accuracy rate of model prediction IP is improved to 85% or above, the method provides timely IP risk prompts for clinicians based on an early warning function of CT image segmentation and feature analysis, and is beneficial to optimizing a treatment scheme, delaying or reducing the probability of occurrence of serious complications, and improving the accuracy rate of the model prediction IP in the pneumonia patient sample. According to the automatic image analysis and prediction system, the working pressure of image doctors can be relieved, the film reading burden is greatly reduced, and the response efficiency of a medical system is improved.

The present application relates to the application of saponin in the preparation of anti-mycoplasma bovum products. Mycoplasma bovum can cause bovine pneumonia, arthritis and bovine mastitis and other diseases, and the drugs for preventing and treating bovine mycoplasma diseases in the art are very limited, and the effect of late treatment is not ideal, mainly through the way of strengthening feeding management for prevention and control. The present application provides the in vitro inhibition activity of dioscin and sodium aescinate on mycoplasma bovum. The prior art is blank in the related research of saponin compounds on the inhibition of mycoplasma. The above compounds not only have good inhibition effect on mycoplasma bovum, but also have less toxicity to normal cells, and have the prospect of developing into anti-mycoplasma bovum drugs.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The application discloses a digital image quantitative dual-mode detection system and method based on a cascade enhanced nano-enzyme, which comprises a probe prepared from a membrane nano-enzyme material, an immunochromatography test strip and a signal automatic analysis system, the nano-enzyme material takes molybdenum disulfide nanosheets as a substrate, sequentially loads large-diameter platinum-iridium alloy particles and small-diameter platinum-iridium alloy particles through polyethylene imine-mediated electrostatic self-assembly, and forms a high-density catalytic active site array. The probe is coupled with specific antibodies on the surface of the nano-enzyme material. Based on the inherent light absorption and peroxidase-like activity of the probe, a dual-mode detection strategy of physical color development-catalytic enhancement is established, high-concentration sample visual preliminary screening and low-concentration sample ultra-sensitive quantitative detection are realized, and combined with an adaptive cross-peak colorimetric quantitative algorithm, individual visual perception differences can be effectively eliminated, and on-site rapid quantitative screening of community-acquired pneumonia pathogens such as streptococcus pneumoniae and legionella pneumophila can be realized.

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

The present disclosure relates to a new use, and mainly relates to the use of an FAK inhibitor, such as IN10018, in the preparation of a drug for treating or preventing interstitial pneumonia, a method for treating or preventing interstitial pneumonia by means of administering a therapeutically effective amount of the FAK inhibitor, such as IN10018, and a pharmaceutical combination product, kit and pharmaceutical composition containing the FAK inhibitor, such as IN 10018, for treating or preventing interstitial pneumonia.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

This invention proposes a random forest-based diagnostic method for Pneumocystis jirovecii pneumonia (PCP), comprising the following steps: collecting case data to form a raw dataset; cleaning and normalizing the feature encoding of the raw dataset; calculating the importance score of each feature based on three indices: permutation importance, Gini importance, and mutual information, converting it into a feature sampling probability distribution, and selecting features with sampling probabilities higher than a preset threshold; constructing a random forest model and training and optimizing it; validating the model performance using a test set and outputting the trained PCP diagnostic model; inputting standardized test samples into the diagnostic model and outputting diagnostic results. This invention solves the industry problems of intolerance to traditional invasive diagnoses, high false positive / false negative rates in routine serological tests, and insufficient generalization ability of existing machine learning models, providing non-invasive, efficient, and universal technical support for early PCP diagnosis, and is suitable for clinical application in medical institutions at all levels.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

The invention belongs to the technical field of biology, and particularly relates to a quintuple fluorescent PCR detection reagent for porcine respiratory pathogens and application of the quintuple fluorescent PCR detection reagent. The quintuple fluorescent PCR detection reagent disclosed by the invention can achieve the purpose of simultaneously identifying and detecting actinobacillus pleuropneumoniae, haemophilus parasuis, mycoplasma hyopneumoniae, pasteurella multocida and / or streptococcus suis, and has the advantages of simplicity, convenience and rapidness in operation, high accuracy, high sensitivity and good repeatability; the method has important significance on rapid and accurate detection and epidemic disease prevention and control of clinical porcine respiratory pathogens.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.